AstraZeneca is planning to gradually withdraw from making its own active pharmaceutical ingredients (APIs) and will use China as the pinnacle of its new outsourcing plans.
AstraZeneca is planning to gradually withdraw from making its own active pharmaceutical ingredients (APIs) and will use China as the pinnacle of its new outsourcing plans.
阿斯利康正计划逐步从自行生产原料药中退出，将中国作为其新的外包计划的重中之重。